Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Decrease in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 233,417 shares, a decrease of 79.7% from the November 30th total of 1,147,847 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,100,765 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 1,100,765 shares, the short-interest ratio is presently 0.2 days. Approximately 1.1% of the shares of the company are short sold.

Analyst Ratings Changes

A number of research firms have weighed in on ENLV. D. Boral Capital reissued a “hold” rating on shares of Enlivex Therapeutics in a research report on Monday, November 24th. Wall Street Zen upgraded Enlivex Therapeutics to a “sell” rating in a research note on Saturday, August 30th. D Boral Capital downgraded Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enlivex Therapeutics in a report on Monday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. One investment analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $10.00.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $0.80 on Thursday. The firm’s 50-day moving average is $0.99 and its 200-day moving average is $1.10. Enlivex Therapeutics has a 52-week low of $0.74 and a 52-week high of $2.10. The company has a market cap of $19.51 million, a price-to-earnings ratio of -1.46 and a beta of 1.49.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. Equities analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

Several institutional investors have recently modified their holdings of the company. Jane Street Group LLC increased its position in shares of Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after purchasing an additional 67,886 shares during the period. Citizens Financial Group Inc. RI bought a new position in Enlivex Therapeutics in the third quarter worth $241,000. Finally, Susquehanna International Group LLP acquired a new stake in Enlivex Therapeutics during the third quarter worth $57,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.